sb 203580 has been researched along with N-cyclopropyl-3-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-4-methylbenzamide in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (N-cyclopropyl-3-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-4-methylbenzamide) | Trials (N-cyclopropyl-3-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-4-methylbenzamide) | Recent Studies (post-2010) (N-cyclopropyl-3-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-4-methylbenzamide) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 6 | 0 | 1 |
| Protein | Taxonomy | sb 203580 (IC50) | N-cyclopropyl-3-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-4-methylbenzamide (IC50) |
|---|---|---|---|
| Heat shock protein beta-1 | Homo sapiens (human) | 0.053 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 4.1905 | |
| Mitogen-activated protein kinase 11 | Homo sapiens (human) | 1 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.0919 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Astolfi, A; Barreca, ML; Brea, J; Cannalire, R; Cecchetti, F; Cecchetti, V; Fallarino, F; Felicetti, T; Kudolo, M; Laufer, SA; Loza, MI; Manfroni, G; Manni, G; Massari, S; Palazzotti, D; Sabatini, S; Tabarrini, O | 1 |
1 other study(ies) available for sb 203580 and N-cyclopropyl-3-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-4-methylbenzamide
| Article | Year |
|---|---|
Discovery of potent p38α MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation.
Topics: Dose-Response Relationship, Drug; Drug Discovery; Drug Evaluation, Preclinical; Healthy Volunteers; Humans; Mitogen-Activated Protein Kinase 14; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship | 2019 |